UCB SA/NV (UCB or the Company) and its subsidiaries (together the Group) is a global biopharmaceutical company focused on severe diseases in three therapeutic areas namely Neurology, Immunology and Bone.
The consolidated financial statements of the Company as at and for the year ended 31 December 2018 comprise the Company and its subsidiaries. Within the Group, UCB Pharma SA and UCB S.R.O, both wholly owned subsidiaries, have branches in the U.K. and Slovakia, respectively, that are integrated into their accounts.
UCB SA/NV, the parent company, is a limited liability company incorporated and domiciled in Belgium.
The registered office is at 60, Allée de la Recherche, B-1070 Brussels, Belgium. UCB SA is listed on the Euronext Brussels Stock Exchange.
The Board of Directors approved these consolidated financial statements and the statutory financial statements of UCB SA for issue on 27 February 2019. The shareholders will be requested to approve the statutory financial statements of UCB SA at their annual meeting on 25 April 2019.
We are developing and applying innovative technologies to design effective medicines for our patients.